Olmesartan Medoxomil

Olmesartan Medoxomil Properties

Melting point	180°C
Boiling point	804.2±75.0 °C(Predicted)
Density	1.38±0.1 g/cm3(Predicted)
Flash point	180°C
storage temp.	2-8°C
solubility	DMSO: soluble20mg/mL, clear
pka	4.15±0.10(Predicted)
form	powder
color	white to beige
Decomposition	180 ºC
InChIKey	UQGKUQLKSCSZGY-UHFFFAOYSA-N
SMILES	C1(CCC)N(CC2=CC=C(C3=CC=CC=C3C3=NNN=N3)C=C2)C(C(OCC2=C(C)OC(=O)O2)=O)=C(C(O)(C)C)N=1
CAS DataBase Reference	144689-63-4(CAS DataBase Reference)
FDA UNII	6M97XTV3HD
ATC code	C09CA08

Pharmacokinetic data

Protein binding	99.7%
Excreted unchanged in urine	35-50%
Volume of distribution	0.24(L/kg)
Biological half-life	10-15 / 36

SAFETY

Risk and Safety Statements

Symbol(GHS)

GHS07

Signal word

Warning

Hazard statements

H302+H312+H332

Precautionary statements

P261-P264-P280-P301+P312-P302+P352+P312-P304+P340+P312

RTECS

NI4014200

HS Code

2934990002

NFPA 704

	0
3		0

Olmesartan Medoxomil price More Price(49)

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Sigma-Aldrich	PHR1851	Olmesartan medoxomil Pharmaceutical Secondary Standard; Certified Reference Material	144689-63-4	200mg	$257	2024-03-01	Buy
Sigma-Aldrich	1478367	Olmesartan medoxomil United States Pharmacopeia (USP) Reference Standard	144689-63-4	100mg	$919	2024-03-01	Buy
TCI Chemical	O0510	Olmesartan Medoxomil >98.0%(HPLC)(T)	144689-63-4	1g	$103	2024-03-01	Buy
TCI Chemical	O0510	Olmesartan Medoxomil >98.0%(HPLC)(T)	144689-63-4	5g	$308	2024-03-01	Buy
Cayman Chemical	11614	Olmesartan Medoxomil ≥98%	144689-63-4	10mg	$32	2024-03-01	Buy

Product number	Packaging	Price	Buy
PHR1851	200mg	$257	Buy
1478367	100mg	$919	Buy
O0510	1g	$103	Buy
O0510	5g	$308	Buy
11614	10mg	$32	Buy

Olmesartan Medoxomil Chemical Properties,Uses,Production

Description

Olmesartan medoxomil was launched in the US as benicar(R), an orally administered treatment for hypertension. Olmesartan, is a new selective and competitive nonpeptide angiotensin II type 1 receptor antagonist and potently inhibits the Ang.ll-induced pressor responses. The drug competitively inhibited binding of [125I1]-All to AT1 receptors in bovine adrenal cortical membranes, but had no effect on binding to AT2 receptors in bovine cerebellar membranes. In comparative clinical studies in patients with essential hypertension, olmesartan reduced sitting cuff diastolic blood pressure significantly more than losartan, valdesartan and ibesartan, while reductions in systolic blood pressure were similar for all treatments. Olmesartan medoxomil was also shown to reduce blood pressure significantly more effectively than losartan and the ACE inhibitor captopril and as effectively as the pbloker atenolol.

Chemical Properties

White to off-white crystalline powder

Originator

Sanky (Japan)

Uses

Olmesartan medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. Olmesartan works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle. By blocking the binding rather than the synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion.
Olmesartan medoxomil is a pro-drug that is de-esterified to the active metabolite, olmesartan. Olmesartan has a dual method of elimination, with about 60% eliminated by the liver and the remainder by the kidney. In situations of impaired renal or hepatic function, the alternative excretion pathway can compensate for the compromised one. Olmesartan is not metabolized by the cytochrome P450 enzyme system and therefore has a low potential for metabolic drug interactions, a feature that may be of importance when treating patients on multiple drug regimens, such as the elderly. Olmesartan is well tolerated and has an excellent safety profile that is comparable to that of placebo. In addition, olmesartan provides 24-h blood pressure control with a once-daily dosing. In head-to-head studies, olmesartan delivered superior blood pressure reduction when compared with other angiotensin-II receptor antagonists at their recommended doses.

Definition

ChEBI: Olmesartan medoxomil is a member of biphenyls.

brand name

Benicar

General Description

Olmesartan Medoxomil is a synthetic imidazole derivative prodrug with an antihypertensive property. Upon hydrolysis, olmesartan medoxomil is converted to olmesartan. Olmesartan selectively binds to the angiotensin type 1 (AT1) receptor of angiotensin II in vascular smooth muscle and adrenal gland, thereby competing angiotensin II binding to the receptor. This prevents angiotensin II-induced vasoconstriction and decreases aldosterone production, thereby preventing aldosterone-stimulated sodium retention and potassium excretion.

Biochem/physiol Actions

Olmesartan medoxomil is a selective Angiotensin II Type I receptor blocker and antihypertensive drug. Olmesartan medoxomil is converted enzymatically to the active form olmesartan.

Clinical Use

Angiotensin-II receptor antagonist:
Hypertension

Side effects

Dizziness or lightheadedness may occur as your body adjusts to the medication. If any of these effects persist or worsen, tell your doctor or pharmacist promptly. To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position.

Synthesis

Olmesartan Medoxomil can be synthesized in 8 steps from diaminomaleonitrile by successive reactions with trialkylorthopropanoate to access 2-propyl-imidazole-45dicarbonitrile, conversion of the two nitrile functions to the corresponding ethyl esters, followed by methylmagnesium bromide addition to give the corresponding 4-(1-hydroxyalkyl)imidazole derivative.
synthesis of Olmesartan Medoxomil
The imidazole ring of olmesartan (18) was constructed with diaminomaleonitrile 155 and trimethylorthobutyrate (156) in CH3CN then xylene to give 157 in 96% yield. Acid hydrolysis of 157 in 6N HCl gave the dicarboxylic acid intermediate. After esterification of the diacid in ethanol in the presence of HCl, diester 158 was treated with MeMgCl to give 4-(1-hydroxyalkyl) imidazole 159 in 95% yield. Alkylation of 159 with biphenyl bromide 160 in the presence of potassium tbutoxide afforded 161 in 80% yield. Ester 161 was then hydrolyzed to free carboxylic acid 162 under basic conditions, and 162 was treated with chloride 163 in the presence of K2CO3 to give ester 164 in 88% yield from 161.Lastly, the trityl group was removed with 25% aqueous acetic acid to give olmesartan (18) in 81% yield.

Drug interactions

Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia hypotension and renal impairment with ACE-Is and aliskiren.
Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
Lithium: reduced excretion (possibility of enhanced lithium toxicity).
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Metabolism

Olmesartan medoxomil is an ester prodrug that is hydrolysed during absorption from the gastrointestinal tract to the active form olmesartan. It is excreted in the urine and the bile as olmesartan; about 35-50% of the absorbed dose is excreted in the urine and the remainder in the bile.

Olmesartan Medoxomil synthesis

Synthesis of Olmesartan Medoxomil from Trityl olmesartan

Olmesartan Medoxomil Preparation Products And Raw materials

Raw materials

Trityl olmesartan Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate 5-(4'-Bromomethyl-1,1'-biphenyl-2-yl)-1-triphenylmethyl-1H-tetrazole N-Trityl Olmesartan Ethyl Ester Trityl Olmesartan Medoxomil

1H-IMidazole-5-carboxylic acid, 4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-, ethyl ester 4-Cloromethyl-5-methyl-1,3-dioxol-2-one

1of2

Preparation Products

Olmesartan Medoxomil Suppliers

Global( 765)Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
Shandong Hengshannuode Pharmaceutical Technology Co., Ltd.	+8615065888978	admin@hsnordpharma.com	China	92	58
Sinoway Industrial co., ltd.	0592-5800732; +8613806035118	xie@china-sinoway.com	China	992	58
Shandong Huisheng Import & Export Co., Ltd.	+86-13176845580 +86-13176845580	da@zhongda-biotech.com	China	248	58
Anhui Zhongda Biotechnology Co., Ltd	+8619956560829	justine@zhongda-biotech.com	China	300	58
Anhui Zhongda Biotechnology Co., Ltd	+8615689548120	linda@zhongda-biotech.com	China	204	58
Anhui Ruihan Technology Co., Ltd	+8617756083858	daisy@anhuiruihan.com	China	994	58
Hangzhou Hyper Chemicals Limited	+86-0086-57187702781 +8613675893055	info@hyper-chem.com	China	149	58
Ouhuang Engineering Materials (Hubei) Co., Ltd	+8617702722807	admin@hbouhuang.com	China	3001	58
Beijing Cooperate Pharmaceutical Co.,Ltd	010-60279497	sales01@cooperate-pharm.com	CHINA	1811	55
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21687	55

Supplier	Advantage
Shandong Hengshannuode Pharmaceutical Technology Co., Ltd.	58
Sinoway Industrial co., ltd.	58
Shandong Huisheng Import & Export Co., Ltd.	58
Anhui Zhongda Biotechnology Co., Ltd	58
Anhui Zhongda Biotechnology Co., Ltd	58
Anhui Ruihan Technology Co., Ltd	58
Hangzhou Hyper Chemicals Limited	58
Ouhuang Engineering Materials (Hubei) Co., Ltd	58
Beijing Cooperate Pharmaceutical Co.,Ltd	55
Henan Tianfu Chemical Co.,Ltd.	55

View Lastest Price from Olmesartan Medoxomil manufacturers

Update time	Product	Price	Min. Order	Purity	Supply Ability	Manufacturer
2024-06-07	Olmesartan Medoxomil 144689-63-4	US $0.00-0.00 / g	1g	99%	100kg	Wuhan Cell Pharmaceutical Co., Ltd
2024-06-04	Olmesartan Medoxomil 144689-63-4	US $0.00 / Kg/Bag	2Kg/Bag	99% up, High Density	20 tons	Sinoway Industrial co., ltd.
2024-05-06	Olmesartan Medoxomil 144689-63-4	US $0.00-0.00 / KG	1KG	99%, USP, EP	5,000KG	Hangzhou Hyper Chemicals Limited

Olmesartan Medoxomil
144689-63-4
US $0.00-0.00 / g
99%
Wuhan Cell Pharmaceutical Co., Ltd

Olmesartan Medoxomil
144689-63-4
US $0.00 / Kg/Bag
99% up, High Density
Sinoway Industrial co., ltd.

Olmesartan Medoxomil
144689-63-4
US $0.00-0.00 / KG
99%, USP, EP
Hangzhou Hyper Chemicals Limited

Olmesartan Medoxomil Spectrum

Olmesartan Medoxomil(144689-63-4)¹HNMR

144689-63-4(Olmesartan Medoxomil)Related Search:

Olmesartan Olmesartan OlMesartan Lactone IMpurity 1-(4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazol-5-yl)ethanone Losartan potassium

Irbesartan Olmesartan Rebeprazole sodium Valganciclovir hydrochloride 4-(1-Methoxy-1-methylethyl)-2-propyl-1H-Imidazole-5-carboxylic acid ethyl ester

Anastrozole Tasosartan EPROSARTAN 4,5-Bismethylene-1,3-dioxolan-2-one Dehydro Olmesartan

OlMesartan MedoxoMil Ethyl Methyl Analog Diethyl 2-propylImidazoledicarbonate OlMesartan MedoxoMil Butyl IMpurity

1of4

(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl] 4-yl)methyl)-4-( OlMesartan MedoxoMil SynoyM:4-(1-Hydroxy-1-Methylethyl)-2-propyl-1-[[2'-(1H-tetazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-1H-iMidazole-5-carboxylic acid (5-Methyl-2-oxo-1,3-dioxol-4-yl)Methyl ester OLMESARTAN MEDOXOMIL USP ORGANIC CHEMICA OMST 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester Olmesartan medoxomil for system suitability Olmesartan MedoxomiI Olmesartan Medoxomi (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hyd 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl-1H-Imidazole-5-carboxylic acid, (5-methyl -2-oxo-1,3-dioxol-4-yl) methyl ester OlmesartanC29H30N6O6 CS-866, 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2(1H-tetazol-5-yl)[1,1biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic Acid (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylicacid(5-Methyl-2-oxo-1,3-dioxol-4-yl)methylester CS-866 Olmesartan medoxomil Olmetec 5-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-3-[2''-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-3H-IMIDAZOLE-4-CARBOXYLIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER 5-(1-Hydroxy-1-methylethyl)-2-propyl-3-[2'-(1H-tet Sanguisorba officinalis L. Olmesartan Medoxomil (100 mg) (5-Methyl-2-oxo-2H-1,3-dioxol-4-yl)Methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}Methyl)-1H-iMidazole-5-carboxylate OlMesartan MedoxoMil (Benicar) (5-Methyl-2-oxo-1,3-dioxol-4-yl)Methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-iMidazole-5-carboxylate Olmesartan Medoxomil USP/EP/BP olmesartan medoxomil olmetec 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2’-(1h-tetazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl esterEuEEuE Olmesartan Medoxomil-USP 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2’-(2H-tetazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic Acid (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2Htetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate Good Quality Olmesartan Medoxomil CAS?144689-63-4?Omst for Anti-Hypertensive (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate Olmesartan Medoxomil (CS 866) 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolecarboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester Olmesartan medoxomil CRS Olmesartan medoxomil for system suitability CRS Olmesartan Medoxomil RS olmesartan medoxomil olmetec 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1h-tetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl esterEuEE Olmesartan medoxomil (Y0001405) Olmesartan MedoxomilQ: What is Olmesartan Medoxomil Q: What is the CAS Number of Olmesartan Medoxomil Q: What is the storage condition of Olmesartan Medoxomil Olmesartan Medoxomil (1478367) Benicar Oimesartan OLMESARTAN MEDOXIMIL Benzenesulfonylchloride,8-(acetylamino)- Olmesartan Medoxomile OLMESARTAN MEDOXOMIL 13.33 % GRANULES OLEMISARTAN MEDAXMIL Olmesartan API Olmesartan Medoxomil (5-Methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan- 2-yl)-2-propyl-1-({4-[2-(2H-1,2,3,4-tetrazol-5- yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylate Olmesartan medoxomil API (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate 144689-63-4 144689-63-5 C29H30N6O C29H30N6O6 Cardiovascular APIs OMNICEF API Inhibitor